Teaching Lecture: Managing the side effects of breast cancer
|
 |
P.A. Ganz (USA) |
Managing the side effects of breast cancer |
Teaching Lecture: CNS metastasis - the role of radiotherapy for brain metastatic spinal cord compression
|
|
D. Rades (Germany) |
CNS metastasis: The role of radiotherapy for brain metastasis and metastatic spinal cord compression |
Teaching Lecture: Patient communication
|
|
L. Fallowfield (United Kingdom) |
Patient communication |
Europa Donna teaching lecture: Breast unit implementation - A National response
|
|
N. O'Higgins (Bahrain) |
Breast unit implementation - A National response |
| |
Keynote symposium: Understanding progression of breast cancer and its clinical implications
|
|
M.J. Bissell (USA) |
Models to study breast cancer invasion and metastases: lessons from normal |
|
R. Clarke (United Kingdom) |
Stem cells and cancer: treatment resistance, markers and novel therapeutic targets |
Clinical science symposium: Multi-targeting therapies in breast cancer
|
|
J. Baselga (Spain) |
Multiple pathway targeting strategies in HER2 overexpressing breast cancers |
|
A. Tutt (United Kingdom) |
Synthetic lethal strategies in ER / HER2 negative breast cancers |
|
E. De Azambuja (Belgium) |
Prognostic and predictive value of central and local hormone receptor assessment in the HERA trial |
|
M. Campone (France) |
Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib |
Clinical science symposium: Precursors and pre-invasive lesions
|
|
C. Van Ongeval (Belgium) |
Radiological diagnosis of precursor and pre-invasive breast lesions |
|
B. Cutuli (France) |
Should all pre-invasive lesions be excised and irradiated? |
Clinical science symposium: Long term sequelae of breast cancer management
|
|
M. Dixon (United Kingdom) |
Late Sequelae of breast cancer surgery |
Clinical science symposium: Gene profiling and treatment of disease
|
|
C. Sotiriou (Belgium) |
Moving from first to second generation multigene expression signatures for treatment |
|
G. von Minckwitz (Germany) |
PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy |
Europa Donna session: Implementation of the European Union Guidelines for quality assurance in breast cancer screening and diagnosis
|
|
S. Knox (Italy) |
Advocacy perspective |